Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 45 citing articles:

Alzheimer's disease drug development pipeline: 2024
Jeffrey L. Cummings, Yadi Zhou, Garam Lee, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2024) Vol. 10, Iss. 2
Open Access | Times Cited: 118
An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery
Qin Huang, Ken Y. Chan, Jason Wu, et al.
Science (2024) Vol. 384, Iss. 6701, pp. 1220-1227
Open Access | Times Cited: 46
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 21
Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms
Steven M. Greenberg, Francesco Bax, Susanne J. van Veluw
Nature Reviews Neurology (2025)
Closed Access | Times Cited: 9
Crossing the blood–brain barrier: emerging therapeutic strategies for neurological disease
Josephine H Pedder, Adam M. Sonabend, Michael D Cearns, et al.
The Lancet Neurology (2025)
Closed Access | Times Cited: 4
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
Byeong‐Hyeon Kim, Sujin Kim, Yunkwon Nam, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions
Jeffrey L. Cummings
Neurotherapeutics (2025), pp. e00570-e00570
Open Access | Times Cited: 2
Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development
Jeffrey L. Cummings, Amanda M. Leisgang Osse, Jefferson W. Kinney, et al.
CNS Drugs (2024) Vol. 38, Iss. 8, pp. 613-624
Open Access | Times Cited: 12
Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy
Kristina Lau, Rebecca Kotzur, Franziska Richter
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Amyloid-β-targeting immunotherapies for Alzheimer's disease
Yi Jin, Qiaofei Du, Mingjie Song, et al.
Journal of Controlled Release (2024) Vol. 375, pp. 346-365
Closed Access | Times Cited: 10
Bridging the gap between theory and treatment: Transition metal complexes as successful candidates in medicine
Sara Abdolmaleki, Alireza Aliabadi, Samad Khaksar
Coordination Chemistry Reviews (2025) Vol. 531, pp. 216477-216477
Closed Access | Times Cited: 1
Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation
Mai Kuriyama, C Wang, Takahide Nagase, et al.
Neurotherapeutics (2025), pp. e00548-e00548
Open Access | Times Cited: 1
Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine
Zixuan Zhao, Yun Liu, Shirong Ruan, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 7825-7845
Open Access | Times Cited: 19
Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer’s Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring
So Yeong Jeong, Chong Hyun Suh, Sang Joon Kim, et al.
Korean Journal of Radiology (2024) Vol. 25, Iss. 8, pp. 726-726
Open Access | Times Cited: 8
The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications
William A. Banks, Elizabeth M. Rhea, May J. Reed, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 11, pp. 101760-101760
Open Access | Times Cited: 8
Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges
Saeid Safiri, Amir Ghaffari Jolfayi, Asra Fazlollahi, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 7
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Sarfaraz K. Niazi, Zamara Mariam, Matthias Magoola
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6683-6683
Open Access | Times Cited: 6
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Judite R.M. Coimbra, Rosa Resende, José B.A. Custódio, et al.
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S53-S78
Closed Access | Times Cited: 6
Amyloid-Related Imaging Abnormalities in Clinical Trials of Gantenerumab in Early Alzheimer Disease
Stephen Salloway, Jakub Wojtowicz, Nicola Voyle, et al.
JAMA Neurology (2024) Vol. 82, Iss. 1, pp. 19-19
Open Access | Times Cited: 6
Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood–brain barrier and interacts with amyloid β
Rebecca Faresjö, Elisabet O. Sjöström, Tiffany D. Dallas, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Targeting Soluble Amyloid Oligomers in Alzheimer’s Disease: A Hypothetical Model Study Comparing Intrathecal Pseudodelivery of mAbs Against Intravenous Administration
Manuel Menéndez‐González
Diseases (2025) Vol. 13, Iss. 1, pp. 17-17
Open Access
Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution
Nathalie Khoury, Michelle E. Pizzo, Claire B. Discenza, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
The blood-brain barrier as a treatment target for neurodegenerative disorders
Ruslan Rust, Abhay P. Sagare, Mingzi Zhang, et al.
Expert Opinion on Drug Delivery (2025)
Closed Access
Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody
Vanessa Schumacher, Solen Pichereau, Juliana Bessa, et al.
Clinical and Translational Medicine (2025) Vol. 15, Iss. 3
Open Access
The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo
Gillian Bonvicini, S. Gojendra Singh, Lisa Sandersjöö, et al.
Fluids and Barriers of the CNS (2025) Vol. 22, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top